2019-04-01 08:28:00 Mon ET
technology social safety nets education infrastructure health insurance health care medical care medication vaccine social security pension deposit insurance
OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome saliva samples and then provides discreet DNA diagnostic test tubes and kits for liquid biopsy, hepatitis, cancer, and HIV etc. In the meantime, OraSure and its subsidiary DNA Genotek serve as a quasi-monopoly with secure economic rent protection in the new biotech market for DNA spit tubes.
As there has been a substantial increase in international demand for cost-effective and affordable DNA tests over the past decade, OraSure gains much from its R&D-driven royalty revenue. As of April 2019, the small-cap stock OraSure trades at a P/E ratio of 16.6x near most long-term average stock market benchmarks. Further, the current stock market capitalization of OraSure is almost 3.4x times total sales and 2.2x times total book assets. From a fundamental perspective, OraSure enjoys juicy profit margins: the gross profit margin of 62.5% exceeds most stock market benchmarks, and the net profit margin hovers in the healthy range of 11%-15% in recent times. As its broad biotech patents and trademarks represent fundamental competitive moats and niches, OraSure continues to dominate in the new specialty market for DNA diagnostic test tubes.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-02-15 11:33:00 Friday ET

President Trump is open to extending the March 2019 deadline for raising tariffs on Chinese imports if both sides are close to mutual agreement. These bilat
2019-05-05 10:34:00 Sunday ET

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate-to-progressive policy proposals. At the age of 76, Biden stands ou
2022-11-05 11:32:00 Saturday ET

CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers an
2018-08-13 12:39:00 Monday ET

White House chief economic adviser Larry Kudlow points out that the recent U.S. dollar strength shows a clear sign of investor confidence and optimism. Gree
2018-03-06 11:35:00 Tuesday ET

The Trump team blocks Broadcom's bid for Qualcomm due to national economic security concerns and 5G telecom network issues. Broadcom makes microchips fo
2027-01-31 12:25:00 Sunday ET

In recent decades, many governments have chosen to run high fiscal deficits on top of sovereign debt mountains so that greater government intervention still